Mr Mark Sullivan is the current CEO of Medicines Development Ltd, which he founded in 2006. He is responsible for strategy, project management and implementation of clinical trials, including first-in-human, proof of concept, phase II, global phase III, phase IIIb design and implementation, and phase IV.
Mark has a clinical research background with over 20 years’ experience in the development of small molecules, therapeutic and prophylactic vaccines and microbicides. This experience includes 10 years with Glaxo (now GSK) at their research and development headquarters in London, United Kingdom, two years with Gilead Sciences at their head office in San Francisco, USA and three years at University of New South Wales as Chief Operating Officer for HIV Vaccines. Mark’s current areas of interest in global health include the preclinical and clinical development of four products and the in-licensing of IP for use in developing countries.